摘要
随着新型高效口服直接抗病毒药物在欧美国家临床上的广泛应用,不但提高了慢性丙型肝炎(丙肝)及肝硬化的临床治愈率,也使我们对丙肝的认识和治疗理念发生了根本性改变。从控制病毒到治愈丙肝,从治疗疾病到以治为防,从应答指导的个体化治疗策略到全口服、泛基因型、短疗程的全覆盖方案。面对这种新的治疗形式,我国现阶段的丙肝防治新策略更值得关注。
With clinical application of efficient oral direct-acting antiviral agents in European and Ammerican countries, patients with chronic hepatitis C or liver cirrhosis may achieve high sustained virological response, and meanwhile our understanding of hepatitis C and its treatment has been changed fundamentally from the control of the virus to the cure of hepatitis C, from clinical care to prevention of hepatitis C by treatment, from response-guided therapy to all-oral, all-genotype and short-course treatment. Facing the new treatment situation, much attention needs to be given to current new prevention and control strategies for hepatitis C in China.
出处
《传染病信息》
2016年第2期71-72,100,共3页
Infectious Disease Information
基金
国家"十二五"科技重大专项(2012ZX10002003)
辽宁省传染性疾病转化医学研究中心建设(2014225020)
关键词
丙型肝炎
治疗学
抗病毒药
hepatitis C
therapeutics
antiviral agents
